Expert Interview
A Second Look: Evaluating the potential of new therapies in development for Waldenstrom macroglobulinemia with a focus on Iopofosine I 131 (CLR131) SM radiotherapeutic from Cellectar and mavorixafor from X4 Pharma
Ticker(s): CLRB, XFORInstitution: Harvard
- Associate Professor of Medicine at Harvard Medical School
- Clinical Director, Bing Center for Waldenstrom Macroglobulinemia where he treats over 1000 patients with WM per year.
- Has secured research grants to study novel non-chemotherapeutic agents for the treatment of WM; running clinical trials evaluating novel agents, such as venetoclax, daratumumab, ulocuplumab and BGB-311.
- Regularly attends international professional seminars, conferences, and patient support group meetings where he lectures on the latest research and treatments for Waldenstrom's Macroglobulinemia and related disorders.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
